NSN Co. Ltd (031860) - Total Liabilities
Based on the latest financial reports, NSN Co. Ltd (031860) has total liabilities worth ₩20.47 Billion KRW (≈ $13.87 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of NSN Co. Ltd to see how much of total assets are deployed in long-term investments.
NSN Co. Ltd - Total Liabilities Trend (2006–2025)
This chart illustrates how NSN Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 031860 total assets.
NSN Co. Ltd Competitors by Total Liabilities
The table below lists competitors of NSN Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PZ Cormay SA
WAR:CRM
|
Poland | zł43.46 Million |
|
CANADIAN NORTH RESOURCES
F:EO0
|
Germany | €3.30 Million |
|
Park Ha Biological Technology Co., Ltd.
NASDAQ:BYAH
|
USA | $1.58 Million |
|
HEBEI CONSTR.GRP CORP YC1
F:H9D
|
Germany | €42.04 Billion |
|
Principal Technologies Inc
V:PTEC
|
Canada | CA$1.32 Million |
|
SeaStar Medical Holding Corporation
NASDAQ:ICU
|
USA | $4.35 Million |
|
COINSILIUM GROUP LTD
F:5CT
|
Germany | €161.47K |
Liability Composition Analysis (2006–2025)
This chart breaks down NSN Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 031860 equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.92 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NSN Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NSN Co. Ltd (2006–2025)
The table below shows the annual total liabilities of NSN Co. Ltd from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩20.47 Billion ≈ $13.87 Million |
+154.73% |
| 2024-12-31 | ₩8.03 Billion ≈ $5.45 Million |
+26.86% |
| 2023-12-31 | ₩6.33 Billion ≈ $4.29 Million |
-72.87% |
| 2022-12-31 | ₩23.35 Billion ≈ $15.82 Million |
-11.64% |
| 2021-12-31 | ₩26.42 Billion ≈ $17.91 Million |
+158.38% |
| 2020-12-31 | ₩10.23 Billion ≈ $6.93 Million |
-77.59% |
| 2019-12-31 | ₩45.63 Billion ≈ $30.92 Million |
+270.74% |
| 2018-12-31 | ₩12.31 Billion ≈ $8.34 Million |
+1.36% |
| 2017-12-31 | ₩12.14 Billion ≈ $8.23 Million |
-47.36% |
| 2016-12-31 | ₩23.07 Billion ≈ $15.63 Million |
+50.33% |
| 2015-12-31 | ₩15.34 Billion ≈ $10.40 Million |
+79.01% |
| 2014-12-31 | ₩8.57 Billion ≈ $5.81 Million |
-22.07% |
| 2013-12-31 | ₩11.00 Billion ≈ $7.45 Million |
-88.26% |
| 2012-12-31 | ₩93.66 Billion ≈ $63.47 Million |
+62.32% |
| 2011-12-31 | ₩57.70 Billion ≈ $39.10 Million |
+77.05% |
| 2010-12-31 | ₩32.59 Billion ≈ $22.08 Million |
+286.94% |
| 2007-12-31 | ₩8.42 Billion ≈ $5.71 Million |
-28.26% |
| 2006-12-31 | ₩11.74 Billion ≈ $7.96 Million |
-- |
About NSN Co. Ltd
DHX Company Co., Ltd. engages in biomedical and distribution businesses in South Korea. The company offers Microbiome to treat intractable skin diseases; REJURUB; and AI digital brain diagnostic device. It also purchases and distributes IT components, including graphics cards, DRAM, CPUs, high-capacity storage, and multi-purpose displays; import and distribution of cosmetics; f and b distribution… Read more